Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sinopep Allsino Bio Pharmaceutical Co EBITDA Margin % Related Terms
Sinopep Allsino Bio Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopep Allsino Bio Pharmaceutical Co EBITDA Margin % Chart
SHSE:688076 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Sinopep Allsino Bio Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopep Allsino Bio Pharmaceutical Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinopep Allsino Bio Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sinopep Allsino Bio Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) has a EBITDA Margin % of 30.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors. This is 10% below median its historical median of 33.46. According to the industry distribution chart, Sinopep Allsino Bio Pharmaceutical Co ranks #157 out of 939 companies in the Biotechnology industry, placing it in the top 16.7%.
Is Sinopep Allsino Bio Pharmaceutical Co's EBITDA Margin % too high?
Sinopep Allsino Bio Pharmaceutical Co's current EBITDA Margin % of 30.14% is 10% below median its 10-year median of 33.46. Based on the distribution chart, Sinopep Allsino Bio Pharmaceutical Co ranks #157 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopep Allsino Bio Pharmaceutical Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopep Allsino Bio Pharmaceutical Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinopep Allsino Bio Pharmaceutical Co ranks #157 out of 939 companies for EBITDA Margin %. This places Sinopep Allsino Bio Pharmaceutical Co in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors. Sinopep Allsino Bio Pharmaceutical Co's current EBITDA Margin % is 30.14%, which is 10% below median its own 10-year median of 33.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopep Allsino Bio Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥58.87, compared to a current price of ¥28.00 — trading 52.4% below its estimated fair value. The current EBITDA Margin % is 30.14%, which is 10% below median its 10-year median of 33.46. Sinopep Allsino Bio Pharmaceutical Co's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076), the current EBITDA Margin % is 30.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥28.00 is trading 52.4% below its estimated GF Value™ of ¥58.87.
GuruFocus considers Sinopep Allsino Bio Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:688076:
EBITDA Margin %: 30.14% (10% below median its 10-year median of 33.46)
GF Value™: ¥58.87 vs. price of ¥28.00 (52.4% below fair value)
No single metric tells the full story. See the SHSE:688076 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinopep Allsino Bio Pharmaceutical Co Business Description
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
65GF Score
Get the complete analysis for SHSE:688076
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688076 has been successfully added to your 
